Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Integral Diagnostics Ltd. ( (AU:IDX) ) just unveiled an announcement.
Integral Diagnostics has reported a strong first-half FY26 performance, underpinned by the recent merger with Capitol Health, which has expanded its operational scale and clinic network. The group delivered revenue of $393.5 million, up 55.6%, and boosted its operating EBITDA margin to 20.6%, with operating NPAT more than doubling and leverage reduced to 2.5 times EBITDA.
Operating EBITDA rose 75.6% to $81.1 million and operating diluted EPS climbed 66.2%, supporting a 32% increase in the fully franked interim dividend to 3.3 cents per share. Management highlighted that merger integration is on track, with more than $14 million in annual synergies already realised, exceeding initial expectations and reinforcing the company’s trajectory for further margin improvement and enhanced shareholder returns.
The most recent analyst rating on (AU:IDX) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on Integral Diagnostics Ltd. stock, see the AU:IDX Stock Forecast page.
More about Integral Diagnostics Ltd.
Integral Diagnostics Limited is an Australian listed provider of medical imaging services, operating a network of diagnostic clinics across Australia and New Zealand. The company focuses on radiology and related imaging services, leveraging scale and clinic coverage to support clinical outcomes and growth in the healthcare diagnostics market.
Average Trading Volume: 583,697
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$905.7M
See more data about IDX stock on TipRanks’ Stock Analysis page.